James P. Allison, PhD, is professor and chair of The University of Texas MD Anderson Cancer Center Department of Immunology in the Division of Basic Science Research. He directs the Immunotherapy Platform and is deputy director of the David H. Koch Center for Applied Research in Genitourinary Cancers. He also is a Howard Hughes Medical Institute Investigator.

His research focuses on T cell response mechanisms and applying that basic understanding to overcome cancer’s evasion of attack by the immune system. These discoveries led to the clinical development of ipilimumab to block CTLA-4, FDA approved to treat melanoma. Ipilimumab and other agents continue to demonstrate effectiveness against other cancers.